Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
May 30 2024 - 3:42AM
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the
“Company” or “Burning Rock”) has recently announced a collaboration
with Bayer to develop next-generation sequencing (NGS)-based
companion diagnostic assays (CDx), aiming to provide diagnostic
methods, to enable treatment choice for patients with cancer in
China, while driving innovation and development in cancer therapy.
This collaboration will focus on the development of companion
diagnostic products in China, jointly developing NGS-based CDx for
Bayer's growing portfolio of precision cancer therapies.
“We are delighted to have established a companion
diagnostics collaboration with Bayer, a global leader in the
biopharmaceutical industry. Burning Rock is committed to the
comprehensive development of companion diagnostics on a global
scale, and we believe that through the integration of our resources
and expertise in the field of cancer diagnosis and treatment, this
collaboration will set a standard and high-quality model for the
joint development of precision diagnostics. We aim to make a
greater contribution to the advancement of precision oncology,
providing more effective treatment options for patients and setting
new benchmarks in the medical field,” said Mr. Han, Founder and CEO
of Burning Rock.
About Burning RockBurning Rock
is a biotechnology company that focuses on the application of next
generation sequencing (NGS) technology in the field of precision
oncology. Its business consists of 1) NGS-based therapy selection
testing for late-stage cancer patients, 2) Global pharmaceutical
services on biomarker detection and companion diagnostics
developing, and 3) Early cancer detection.
For more information, please visit:
us.brbiotech.com
Enquiries:Contact: IR@brbiotech.com
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Aug 2023 to Aug 2024